目的 研究龍金通淋膠囊聯(lián)合左氧氟沙星治療Ⅲ型前列腺炎的療效,為臨床上Ⅲ型前列腺炎的藥物治療提供依據(jù)。方法 選擇2013年10月—2015年6月天津中醫(yī)藥大學(xué)第一附屬醫(yī)院泌尿外科收治的Ⅲ型前列腺炎患者80例,隨機(jī)分為對(duì)照組和治療組,每組各40例。對(duì)照組患者口服鹽酸左氧氟沙星片,0.2 g/次,2次/d。治療組在對(duì)照組治療基礎(chǔ)上口服龍金通淋膠囊,3粒/次,3次/d。兩組均連續(xù)治療8周。觀察兩組的臨床療效,同時(shí)比較兩組慢性前列腺炎癥狀指數(shù)(NIH-CPSI)評(píng)分、前列腺液白細(xì)胞數(shù)的變化情況。結(jié)果 治療后,對(duì)照組和治療組的總有效率分別為62.5%、87.5%,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,兩組前列腺液白細(xì)胞數(shù)、疼痛評(píng)分、排尿癥狀評(píng)分、生活質(zhì)量影響評(píng)分和NIH-CPSI總評(píng)分均較治療前顯著降低,同組治療前后差異具有統(tǒng)計(jì)學(xué)意義(P<0.05);且治療后,治療組這些觀察指標(biāo)顯著低于對(duì)照組,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 龍金通淋膠囊聯(lián)合左氧氟沙星治療Ⅲ型前列腺炎具有較好的臨床療效,可改善患者的NIH-CPSI評(píng)分,降低前列腺液白細(xì)胞數(shù)目,具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical effect of Longjin Tonglin Capsules combined with levofloxacin in treatment of type III prostatitis, to provide clinical basis of drug treatment for Ⅲ Type of prostatitis. Methods Patients (80 cases) with type III prostatitis in Department of Urological Surgery of First Teaching Hospital of Tianjin University of TCM from October 2013 to June 2015 were randomly divided into control and treatment groups, and each group had 40 cases. The patients in the control group were po administered with Levofloxacin Hydrochloride Tablets, 0.2 g/time, twice daily. The patients in the treatment group were po administered with Longjin Tonglin Capsules on the basis of control group, 3 grains/time, three times daily. The patients in two groups were treated for eight weeks. After treatment, the clinical efficacies were evaluated, and the changes of NIH-CPSI scores and leukocyte number of prostate fluid in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 62.5% and 87.5%, respectively, and there were differences between two groups (P< 0.05). After treatment, leukocyte number of prostate fluid, pain score, urination symptom score, quality of life score, and NI-CPSI total score in two groups were significantly decreased, and the difference was statistically significant in the same group (P< 0.05). After treatment, the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P< 0.05). Conclusion Longjin Tonglin Capsules combined with levofloxacin has clinical curative effect in treatment of type III prostatitis, and can improve the NIH-CPSI score, also can reduce the leukocyte number of prostate fluid, which has a certain clinical application value.